نتایج جستجو برای: montanide

تعداد نتایج: 327  

Journal: :Cancer immunology research 2013
Takemasa Tsuji Paul Sabbatini Achim A Jungbluth Erika Ritter Linda Pan Gerd Ritter Luis Ferran David Spriggs Andres M Salazar Sacha Gnjatic

Vaccination of patients with ovarian cancer with overlapping long peptides (OLP) from cancer-testis antigen NY-ESO-1 and poly-ICLC in Montanide-ISA-51 (Montanide) was found to consistently induce integrated immune responses (antibody, CD4(+), and CD8(+) T cells). Using detailed methods, we investigated the respective effects of poly-ICLC and Montanide adjuvant on pre- and postvaccine NY-ESO-1-s...

2015
Stephane Ascarateil Aude Puget Marie-Eve Koziol

Introduction Montanide ISA 51 VG and Montanide ISA 720 VG are two novel adjuvants dedicated to human therapeutic vaccines. They have been used in more than 200 clinical trials involving cancer, AIDS, malaria or autoimmune disease vaccines and involving an accrual of more than 20000 patients. The adjuvants are rendering stable water-in-oil emulsions when mixed with water based antigenic media. M...

2015
Abdel Aziz

Water in oil emulsion fowl cholera vaccine was prepared using Montanide ISA-70-VG oil as alternative adjuvant to the used white mineral oil with span-80. The two vaccines were comparatively evaluated in SPF chickens. Each vaccine was inoculated in a group of 40 chickens while the third group of 40 chickens was kept as non-vaccinated control. It was noticed that the Montanide ISA-70-VG formulate...

Journal: :Pathogens 2023

There is an urgent need to produce a vaccine for Chlamydia trachomatis infections. Here, using the muridarum major outer membrane protein (MOMP) as antigen, four adjuvant combinations IVAX-1 (MPLA+CpG-1018+AddaVax), IVAX-2 (MPLA+CpG-1018+AS03), CpG-1826+Montanide ISA 720 VG (CpG-1826+Mont) and CpG-1018+Montanide (CpG-1018+Mont), were tested their local reactogenicity ability elicit protection i...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Paul Sabbatini Takemasa Tsuji Luis Ferran Erika Ritter Christine Sedrak Kevin Tuballes Achim A Jungbluth Gerd Ritter Carol Aghajanian Katherine Bell-McGuinn Martee L Hensley Jason Konner William Tew David R Spriggs Eric W Hoffman Ralph Venhaus Linda Pan Andres M Salazar Catherine Magid Diefenbach Lloyd J Old Sacha Gnjatic

PURPOSE Long peptides are efficiently presented to both CD4(+) and CD8(+) T cells after intracellular processing by antigen-presenting cells. To investigate the safety and in vivo immunogenicity of synthetic overlapping long peptides (OLP) from a human tumor self-antigen, we conducted a phase I clinical trial with OLP from cancer-testis antigen NY-ESO-1 in various adjuvant combinations. EXPER...

Journal: :Slovenian Veterinary Research 2023

The poultry industry depends heavily on immunization, particularly with live attenuated vaccines. These vaccines are commonly not adjuvanted and can be either injected or delivered in birds’ mucosa. In the current study we evaluated protective efficacy of non-adjuvanted Newcastle disease virus (LaSota strain) Three NDV were used to vaccinate three groups chickens. same immunizations administere...

2017
R. Abd El-Aziz

In the present study, efficacy of two prepared combined vaccines against salmonellosis and infectious coryza in poultry has been studied. Two vaccines were prepared using Salmonella Typhimurium and Enteritidis combined with Avibacterium paragallinarum serovars A, B, and C. one vaccine was adjuvanated with aluminium hydroxide gel and the other adjuvanated with montanide ISA71. The two vaccines w...

2018
Hongtao Liu Yuanyuan Zha Noura Choudhury Gregory Malnassy Noreen Fulton Margaret Green Jae-Hyun Park Yusuke Nakamura Richard A Larson Andres M Salazar Olatoyosi Odenike Thomas F Gajewski Wendy Stock

Background The optimal strategy for vaccination to induce CD8+ T cell responses against WT1 is not known. Methods A pilot randomized study in HLA-A02+ patients to receive vaccination with WT1 in Montanide or in poly ICLC, a TLR3 agonist, to explore the novel immune adjuvant was conducted. Seven patients were randomized. Four patients received WT1 in Montanide, and three with WT1 in poly ICLC....

2012
J. A. Junco

Previous studies with Gonadotropin Releasing Hormone (GnRH/LHRH) vaccines have demonstrated the usefulness of immunization against this hormone in prostate cancer. To this purpose, we generated the completely synthetic GnRHm1-TT peptide which has been validated in a proof of concept formulated together with Montanide ISA 51 adjuvant. Such vaccine preparation induced a significant anti-GnRH immu...

Journal: :Cancer immunology research 2015
Rachel Lubong Sabado Anna Pavlick Sacha Gnjatic Crystal M Cruz Isabelita Vengco Farah Hasan Meredith Spadaccia Farbod Darvishian Luis Chiriboga Rose Marie Holman Juliet Escalon Caroline Muren Crystal Escano Ethel Yepes Dunbar Sharpe John P Vasilakos Linda Rolnitzsky Judith Goldberg John Mandeli Sylvia Adams Achim Jungbluth Linda Pan Ralph Venhaus Patrick A Ott Nina Bhardwaj

The Toll-like receptor (TLR) 7/8 agonist resiquimod has been used as an immune adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given in combination with Montanide (Seppic) with or without resiquimod in patients with high-risk melanoma. In part I of the study, patients received 100 μg of full-length NY-ESO-1 protein emulsified in 1.25...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید